Adaptive Biotechnologies Corp Insider Trading for November 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptive Biotechnologies Corp for November 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 416 | 2,608 | 2,084 | |
| Nov 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 48.86 | 416 | 20,326 | 0 | 416 to 0 (-100.00 %) |
| Nov 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 416 | 2,608 | 416 | 0 to 416 |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 49,560 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 66,240 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 82,920 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.54 | 900 | 43,686 | 1,778,180 | 1.8 M to 1.8 M (-0.05 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.75 | 4,360 | 208,190 | 1,779,080 | 1.8 M to 1.8 M (-0.24 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.69 | 3,773 | 176,161 | 1,783,440 | 1.8 M to 1.8 M (-0.21 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 49,560 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.60 | 7,647 | 348,703 | 1,787,213 | 1.8 M to 1.8 M (-0.43 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 66,240 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 82,920 | |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.52 | 13,480 | 654,050 | 1,778,180 | 1.8 M to 1.8 M (-0.75 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.54 | 900 | 43,686 | 1,778,180 | 1.8 M to 1.8 M (-0.05 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.64 | 2,000 | 95,280 | 1,791,660 | 1.8 M to 1.8 M (-0.11 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.75 | 4,360 | 208,190 | 1,779,080 | 1.8 M to 1.8 M (-0.24 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.68 | 1,200 | 56,016 | 1,793,660 | 1.8 M to 1.8 M (-0.07 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.69 | 3,773 | 176,161 | 1,783,440 | 1.8 M to 1.8 M (-0.21 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.60 | 7,647 | 348,703 | 1,787,213 | 1.8 M to 1.8 M (-0.43 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.68 | 5,633 | 262,948 | 1,778,180 | 1.8 M to 1.8 M (-0.32 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.84 | 11,047 | 506,394 | 1,783,813 | 1.8 M to 1.8 M (-0.62 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.52 | 13,480 | 654,050 | 1,778,180 | 1.8 M to 1.8 M (-0.75 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.64 | 2,000 | 95,280 | 1,791,660 | 1.8 M to 1.8 M (-0.11 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.68 | 1,200 | 56,016 | 1,793,660 | 1.8 M to 1.8 M (-0.07 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.68 | 5,633 | 262,948 | 1,778,180 | 1.8 M to 1.8 M (-0.32 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.84 | 11,047 | 506,394 | 1,783,813 | 1.8 M to 1.8 M (-0.62 %) |
| Nov 19 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Nov 13 2020 | ADPT | Adaptive Biotechno ... | VIKING GLOBAL INVESTORS LP | 10% Owner | Sell | S | 49.52 | 2,500,000 | 123,787,500 | 30,993,708 | 33.5 M to 31 M (-7.46 %) |
| Nov 13 2020 | ADPT | Adaptive Biotechno ... | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | Sell | S | 49.52 | 2,500,000 | 123,787,500 | 30,993,708 | 33.5 M to 31 M (-7.46 %) |
| Nov 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 30,000 | 189,600 | 520,000 | |
| Nov 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 50.92 | 1,760 | 89,619 | 1,000 | 2.8 K to 1,000 (-63.77 %) |
| Nov 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 49.63 | 11,089 | 550,347 | 2,760 | 13.8 K to 2.8 K (-80.07 %) |
| Nov 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 48.67 | 17,151 | 834,739 | 13,849 | 31 K to 13.8 K (-55.33 %) |
| Nov 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 30,000 | 189,600 | 31,000 | 1,000 to 31 K (+3,000.00 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 233,700 | |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 244,800 | |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 255,900 | |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 52.50 | 900 | 47,250 | 679 | 1.6 K to 679 (-57.00 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 51.57 | 8,700 | 448,659 | 1,579 | 10.3 K to 1.6 K (-84.64 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 50.48 | 1,500 | 75,720 | 10,279 | 11.8 K to 10.3 K (-12.73 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 50.88 | 3,846 | 195,684 | 679 | 4.5 K to 679 (-84.99 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 50.00 | 7,254 | 362,700 | 4,525 | 11.8 K to 4.5 K (-61.58 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 50.98 | 1,300 | 66,274 | 679 | 2 K to 679 (-65.69 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 50.20 | 9,800 | 491,960 | 1,979 | 11.8 K to 2 K (-83.20 %) |
| Nov 06 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 1,563 | 11,363 | 40,625 | |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 59,896 | |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,605 | 17,063 | 31,250 | |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 46.14 | 1,074 | 49,554 | 0 | 1.1 K to 0 (-100.00 %) |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 45.47 | 5,698 | 259,088 | 1,074 | 6.8 K to 1.1 K (-84.14 %) |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 1,563 | 11,363 | 6,772 | 5.2 K to 6.8 K (+30.01 %) |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 5,209 | 2.6 K to 5.2 K (+99.96 %) |
| Nov 04 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,605 | 17,063 | 2,605 | 0 to 2.6 K |